October 01, 2016 2:38 PM ET

Pharmaceuticals

Company Overview of Novo Nordisk, Inc.

Company Overview

Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.

100 College Road West

Princeton, NJ 08540

United States

Founded in 1982

Phone:

609-987-5800

Fax:

609-919-7713

Key Executives for Novo Nordisk, Inc.

President
Age: 56
Senior Vice President of Finance and Operations
Age: 49
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Age: 62
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2016.

Novo Nordisk, Inc. Key Developments

Novo Nordisk, Inc. Presents at BioNJ's 4th Annual CEO Summit, Sep-23-2016 10:15 AM

Novo Nordisk, Inc. Presents at BioNJ's 4th Annual CEO Summit, Sep-23-2016 10:15 AM. Venue: Bridgewater Marriott, New Jersey, United States. Speakers: Jesper Høiland, Executive Vice President.

Novo Nordisk Inc. Recalls Six Batches of the Glucagen Hypokit in the United States

Novo Nordisk Inc. is recalling six batches of the GlucaGen® HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). GlucaGen® HypoKit® is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated with insulin. A syringe with a detached needle cannot be used as prescribed. Untreated hypoglycemia can eventually lead to unconsciousness and seizures, which can prove fatal. If the blood glucose levels are not quickly restored, continuing hypoglycemia can lead to a decline in brain glucose levels which manifests through a variety of symptoms including cognitive dysfunction, sweating, tremors, convulsion and eventually coma or death. Novo Nordisk conducted an investigation which showed that a small number (0.006%) of needles could be detached from the syringe in certain batches of GlucaGen® HypoKit®. To protect patient safety, Novo Nordisk is recalling affected batches from wholesalers, pharmacies and patients in the U.S. It is estimated that out of the 71,215 pens being recalled, four pens could be defective. This recall includes GlucaGen® HypoKit® batch numbers: Batch: FS6X270, Expiry: September 30, 2017; Batch: FS6X296, Expiry: September 30, 2017; Batch: FS6X538, Expiry: September 30, 2017; Batch: FS6X597, Expiry: September 30, 2017; Batch: FS6X797, Expiry: September 30, 2017; and Batch: FS6X875, Expiry: September 30, 2017. The affected products were distributed starting February 15, 2016. Novo Nordisk is working as quickly as possible and in collaboration with the U.S. Food and Drug Administration (FDA) to recall affected products from the marketplace, including those in the possession of patients. To date, Novo Nordisk is not aware of any known adverse events resulting from the use of the recalled batches.

Novo Nordisk, Inc. Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-13-2016 04:45 PM

Novo Nordisk, Inc. Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-13-2016 04:45 PM. Venue: Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Aaron Schwartz, Director, R&D Innovation Sourcing.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novo Nordisk, Inc., please visit www.novonordisk-us.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.